Abstract for longer-term follow-up and additional data analysis of Pivotal Phase 2 FELIX study of obe-cel for adult r/r B-ALL selected for an oral presentation at ASCOGlobeNewsWire • Wednesday
Autolus Therapeutics to Report First Quarter 2024 Financial Results and Host Conference Call on May 14, 2024GlobeNewsWire • Tuesday
Autolus Therapeutics Reports Full Year 2023 Financial Results and Business UpdatesGlobeNewsWire • 03/14/24
Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing siteGlobeNewsWire • 03/12/24
Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024GlobeNewsWire • 02/29/24
Strength Seen in Autolus Therapeutics PLC Sponsored ADR (AUTL): Can Its 6.3% Jump Turn into More Strength?Zacks Investment Research • 02/12/24
BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage ProgramsGlobeNewsWire • 02/08/24
Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)GlobeNewsWire • 01/22/24
Autolus Therapeutics: Pivotal Trial Using Familiar Approach, Possible Approval Coming FastSeeking Alpha • 12/18/23
Autolus Therapeutics Presents Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2023GlobeNewsWire • 12/10/23
Autolus Therapeutics Submits Biologics License Application to U.S. Food and Drug Administration for obecabtagene autoleucel (obe-cel) for Patients with Relapsed/refractory (r/r) Adult B-Cell Acute Lymphoblastic Leukemia (ALL)GlobeNewsWire • 11/27/23
Autolus Therapeutics to Host Analyst / Investor event at the American Society of Hematology (ASH) Annual Meeting 2023GlobeNewsWire • 11/15/23
Autolus Therapeutics Reports Third Quarter 2023 Financial Results and Business UpdatesGlobeNewsWire • 11/02/23
Autolus Therapeutics to host virtual event to discuss the company's obe-cel program in systemic lupus erythematosusGlobeNewsWire • 10/17/23
Correction - Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023GlobeNewsWire • 10/11/23
Autolus Therapeutics to report third quarter 2023 financial results and host conference call on November 2, 2023GlobeNewsWire • 10/11/23